Search Within

Karen Anne Autio

Formats
  1. Meeting Abstract (77)
  2. Journal Article (40)
  3. Review (3)
Groups
  1. Department of Medicine (120)
  2. Genitourinary Oncology Service (120)
  3. Solid Tumor Oncology Division (120)
  4. Hematologic Malignancies, Division of (30)
  5. GSK Faculty (21)
  6. Epidemiology and Biostatistics (14)

More Groups

People
  1. Howard Scher (46)
  2. Michael Morris (36)
  3. Dana Rathkopf (34)
  4. Susan Slovin (28)
  5. Daniel Danila (22)
  6. Wassim Abida (15)

More People

Years
  1. 2025 (5)
  2. 2024 (6)
  3. 2023 (7)
  4. 2022 (7)
  5. 2021 (7)
  6. 2020 (8)

More Years

Publications
  1. Journal of Clinical Oncology (48)
  2. Annals of Oncology (18)
  3. Journal for ImmunoTherapy of Cancer (11)
  4. Clinical Cancer Research (8)
  5. Journal of Immunotherapy and Precision Oncology (3)
  6. Cancer (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (50)
  2. Oxford University Press (18)
  3. Biomed Central Ltd (11)
  4. American Association for Cancer Research (10)
  5. Elsevier Inc. (5)
  6. Elsevier Science, Inc. (5)

More Publishers

Results (120)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)
    Journal Article

    Hecht, J. R.; Papadopoulos, K. P.; Falchook, G. S.; Patel, M. R.; Infante, J. R.; Aljumaily, R.; Wong, D. J.; Autio, K. A.; Wainberg, Z. A.; Bauer, T. M.; more...
    Investigational New Drugs (2021)

    Fulltext@MSK | Save
  • Immunomodulatory activity of a colony-stimulating factor-1 receptor inhibitor in patients with advanced refractory breast or prostate cancer: A phase I study
    Journal Article

    Autio, K. A.; Klebanoff, C. A.; Schaer, D.; Kauh, J. S. W.; Slovin, S. F.; Adamow, M.; Blinder, V. S.; Brahmachary, M.; Carlsen, M.; Comen, E.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Evaluation of immune-related adverse events (irAE): Utilizing the patient-reported outcomes of the common terminology criteria for adverse events (PRO-CTCAE) in a phase II study of ipilimumab (ipi) in men with castration-sensitive prostate cancer (CSPC)
    Meeting Abstract

    Vargas Pivato de Almeida, D.; Anderson, J.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Dayan, E. S.; Curley, T.; Arauz, G.; Baser, R. E.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Changes in Ki-67 and cleaved caspase-3 (CC3) with short term androgen deprivation therapy (ADT) prior to prostatectomy as part of a trial in intermediate and high-risk prostate cancer (PC)
    Meeting Abstract

    Vargas Pivato de Almeida, D.; Chen, Y. B.; Autio, K. A.; Carver, B. S.; Slovin, S. F.; Danila, D. C.; Scher, H. I.; Touijer, K. A.; Rathkopf, D. E.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Ben, Tran; Horvath, L.; Rettig, M.; Fizazi, K.; Lolkema, M. P.; Dorff, T. B.; Greil, R.; Machiels, J. P. H.; Autio, K. A.; Rottey, S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Phase 1 study of AMG 160, a half-life extended BiTE(R) (Bispecific T-cell engager) therapy targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Dorff, T.; Rettig, M.; Machiels, J. P.; Lolkema, M.; Autio, K.; Greil, R.; Rottey, S.; Adra, N.; Salvati, M.; Poon, S.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Tran, B.; Horvath, L.; Dorff, T.; Rettig, M.; Lolkema, M. P.; Machiels, J. P.; Rottey, S.; Autio, K.; Greil, R.; Adra, N.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Immune checkpoint blockade for prostate cancer: Niche role or next breakthrough?
    Review

    Vargas P. de Almeida, D.; Fong, L.; Rettig, M. B.; Autio, K. A.
    American Society of Clinical Oncology Educational Book (2020)

    Fulltext@MSK | Save
  • Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy targeting prostate-specific membrane antigen (PSMA), in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Tran, B.; Horvath, L.; Dorff, T. B.; Greil, R.; Machiels, J. P. H.; Roncolato, F.; Autio, K. A.; Rettig, M.; Fizazi, K.; Lolkema, M. P.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Probody therapeutics: An emerging class of therapies designed to enhance on-target effects with reduced off-tumor toxicity for use in immuno-oncology
    Review

    Autio, K. A.; Boni, V.; Humphrey, R. W.; Naing, A.
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save